Abstract Ankylosing spondylitis (AS) is characterized by gradual cementation of the vertebrae, a process that is described by excessive extracellular matrix remodeling. Specific matrix metalloproteinase (MMP)-derived collagen fragments are released to the circulation, and measurement of those might act as biomarkers of ankylosis. The aim of the study was to investigate the diagnostic value of five novel assays measuring different collagen species. Five newly developed ELISAs measuring MMP-degraded collagen fragments in serum of 40 AS patients and 40 agematched controls were measured: collagen type I (C1M), type II (C2M), type III (C3M), type IV (C4M) and type VI (C6M) as well as the bone formation marker osteocalcin. The levels of the five collagen neoepitopes were significantly higher in AS patients, except for osteocalcin. Cartilage degradation (C2M) was only significantly correlated with the basement membrane (C4M) in the AS patients. In contrast, C3M was significantly correlated with all of the other collagen markers. The highest diagnostic value was achieved when combining the C2M, C3M and C6M markers, AUC 87% (P \ 0.0001). Moreover, a combination of the markers correlated with the clinical mSASS score (P = 0.004, R = 0.44). Novel and unique biomarkers of tissue remodeling may provide diagnostic value and aid in understanding of the AS pathology. Each of the biomarkers tells a unique story, and by combining them in a panel there, we found a strong correlation with mSASSS. We speculate that such panel will be a valuable tool for monitoring patients as effect of treatment, for the prediction of responders and for diagnostic purposes.
Introduction
Rheumatoid diseases such as ankylosing spondylitis (AS), osteoarthritis (OA) and rheumatoid arthritis (RA) are partly described by accelerated joint deterioration, including turnover of the surrounding ECM. The resulting protein fragments, called neoepitopes, are released into the circulation and could serve as measures of tissue and joint destruction [1] . Enzymatic cleavage of collagens involves several proteases counting matrix metalloproteinases (MMPs), which are synthesized by chondrocytes, osteoclasts and fibroblastic cells in response to cytokines and growth factors [2] .
AS is a form of chronic inflammation of the spine and the sacroiliac joints. Over time, chronic inflammation of the spine can lead to complete ankylosis of the vertebrae [3] , a process whose molecular pathology still requires investigation and further clarification. AS is also a systemic disease that affects other tissues throughout the body and includes inflammation in or injury to other joints, as well as organs, such as eyes, heart, lungs and kidneys [4] . AS shares many features with several other forms of spondyloarthritis, such as reactive and psoriatic arthritis, as well as arthritis associated with Crohn's disease and ulcerative colitis [5] . The inflammation-related processes in AS may resemble the reparative processes that occur in fibrosis. Indeed, fusion of the joint seems to involve molecular processes that include increased MMP activity and collagen deposition that are seen in most types of connective tissue turnover.
Extracellular matrix (ECM) remodeling is a key process of tissue homeostasis [6, 7] . Specific proteolytic activities are a prerequisite for a range of cellular functions and interactions within the ECM [8] . These specific activities are precisely coordinated under physiological situations, with a specified sequence of events resulting in controlled tissue turnover. In pathological situations such as inflammation, the normal repair response is disturbed [9] , leading to excessive remodeling and tissue turnover. The consequence of this ECM remodeling is the release of a range of degradation products of proteins generated by the proteases expressed locally in the pathologically affected area. The degradation fragments result in the exposure of de novo sites in the proteins, referred to as neoepitopes. These protein degradation fragments may be specific for the tissue of origin and for the involved enzymes and may consequently be used for the design of molecular biochemical markers [1] .
Endopeptidases, such as matrix metalloproteinases (MMPs), play a major role in the degradation of ECM proteins such as collagens and proteoglycans [10, 11] . Recently, neoepitope-based biochemical markers found in urine and serum have received increased attention for their diagnostic and prognostic potential [1] . For example, in slowly progressing diseases, such as osteoporosis and osteoarthritis, bone resorption and cartilage degradation markers have been studied extensively [12] .
The aims of the present study were to investigate the serological level of five new neoepitope-specific biomarkers of collagen degradation, which are associated with ECM remodeling of connective tissue, cartilage and bone, and to further investigate the combination of these novel biomarkers and their association with the clinical score of AS.
Methods

Healthy subjects and AS patients
The patients and the non-disease controls were recruited to the Department of Medicin 3 of the University of Erlandgen-Nurember. The patients were informed about the research study, and all signed an informed consent. The study was approved by the Ethical Committee of the University of Erlangen-Nuremberg. Serum samples were retrieved from patients diagnosed with ankylosing spondylitis (AS) according to the modified New York criteria and from sex and age-matched non-diseased controls (Table 1 ). Total C-reactive protein (CRP, full-length human CRP (commercial kit Quantikine from R&D System, Abingdon, UK)) was measured for all subjects included in the study. BASDAI and mSASSS were registered for the each of the AS patients ( Table 1 ). Eighteen of the AS patients had been treated with TNF inhibitor, however, in different doses and at different time points, prior to this retrospective study.
Enzyme-linked immunosorbent assays
Five different collagen degradation markers were assessed using five new competitive ELISAs developed in-house. The assays measure MMP-generated neoepitope fragments of collagen type I C1M [13] , II (C2M aka CIIM) [14] , III (C3M) [15] , IV (C4M) and VI (C6M). The technical performances of the assays are briefly described in Table 2 ; the assays are thoroughly described elsewhere. In brief, a 96-well streptavidin plate was coated with the appropriate biotinylated synthetic peptide dissolved in assay buffer and incubated for 30 min at 20°C. Peptide calibrator or sample was added to appropriate wells, and then 100 lL of a conjugated monoclonal antibody against the target sequence was added to wells and incubated. The mix of primary antibody and samples was incubated for 2 h at 20°C or 20 h at 4°C (depending on the individual assay). After thorough washing of the microtiter plate, 100 lL tetramethylbenzinidine (TMB) (KemEn-Tec cat.438OH) was added and the plate was incubated for 15 min at 20°C in the dark. All the above incubation steps included shaking at 300 rpm. After each incubation step, the plate was washed five times in washing buffer (20 mM Tris, 50 mM NaCl, pH 7.2). The TMB reaction was stopped by adding 100 lL of stopping solution (1% HCl) and measured at 450 nm with 650 nm as the reference. A calibration curve was plotted using a 4-parametric mathematical fit model. Osteocalcin was measured using the N-MID assay and run according to the manufacturer's instructions (Immunodiagnostic Systems, Frankfurt am Main, Germany) [16] .
Statistics
The serum levels of the individual biomarkers between the two groups were compared using two-sided non-parametric Mann-Whitney test. Biomarkers were correlated with each other by non-parametric Spearman's test. Area under the curve was measured on ROC calculations. Odds ratios (OR) for having AS were extrapolated from a 2 9 2 contingency table where all subjects were classified as having normal (within 2SD of the mean of the normal population) or high ([2SD) levels of the biomarker. The combination of biomarkers was investigated by the summation of normalized biomarker data; lowest value in the population was set at 0 and highest at 1. Pearson's correlation between the markers and the mSASSS status was examined on normalized and log-transformed biomarkers' data. Results were considered significant when P \ 0.05.
Results
The discriminative properties of each of the individual collagen biomarkers compared with osteocalcin Serum levels of biomarkers of collagen metabolism in AS patients and non-diseased controls were assessed. None of the collagen markers measures were related to gender (P [ 0.05, data not shown). Only osteocalcin was correlated with age and only in the diseased group (R = -0.51, P = 0.0007). The mean serum levels of C1M (Fig. 1a) , C2M (Fig. 1b) , C3M (Fig. 1c), C4M (Fig. 1d) and C6M (Fig. 1e) were significantly elevated in AS patients compared with age-matched controls. However, there was no difference in the serum level of osteocalcin between controls and AS patients (Fig. 1f) .
The discriminative power of the individual markers was calculated by receiver-operator characteristics (ROC). The area under curve is shown in Table 4 . C3M had the highest discriminating power, 0.85 (CI 95%; 0.76-0.93), followed by C6M, 0.82 (CI 95%; 0.73-0.91), and C2M, 0.75 (CI 95%; 0.64-0.86) (Fig. 2) . The AUC for C3M was significantly higher than the osteocalcin, 0.59 (CI 95%; 0.46-0.71), and C4M, 0.69 (CI 95%; 0.57-0.81). C2M, 0.75 (CI 95%; 0.64-0.86), and C6M were borderline significantly higher (P = 0.055) compared with osteocalcin ( Fig. 2) . No difference was seen between C1M, 0.72 (CI 95%; 0.61-0.83), and osteocalcin (Fig. 2) .
Correlation between individual biomarkers of collagen turnover
There was a strong correlation between C3M and C6M, C1M and C4M, respectively, in both the AS patient group and the non-diseased controls (Table 3 ). In contrast, C3M did neither correlate with C2M nor with osteocalcin. The correlation between C2M and osteocalcin, which was observed in the non-diseased control group, was not apparent in AS patients, which could suggest an uncoupling of cartilage Association with modified stoke ankylosing spondylitis spine score (mSASSS)
To investigate the relationship between the markers of collagen turnover and burden of disease, correlations between the individual markers of collagen metabolism and the mSASSS score, which assesses the degree of new bone formation in the spine, were analyzed. C1M (Fig. 3a) , C2M (Fig. 3b) , C4M (Fig. 3d) and C6M (Fig. 3e) were weakly correlated with the mSASSS, suggesting that increased turnover of collagen types II, IV and VI is related burden of disease. Interestingly, C3M did not show any correlation with the mSASSS, suggesting that C3M was less dependent on burden of disease monitored by mSASSS (Fig. 3c) . In contrast to the collagen markers, osteocalcin (Fig. 3f) . Similar correlations were investigated for BASDAI; however, no association was observed (data not shown).
Algorithmic combination of the collagen biomarkers
The three biomarkers that had the highest discriminative value, C2M, C3M and C6M (Fig. 2) , were investigated further to see whether the discriminative value could be further increased. No colinearity was observed between these markers (Table 3 ). The combination C2M:C3M:C6M gave a higher AUC than C3M, which was the biomarker that gave the highest AUC (Table 4) . Furthermore, the precision was also improved; hence, the CI 95% was narrower. Including the C1M, C4M and osteocalcin into the algorithm decreased the discriminative value (Table 4) . Osteocalcin was inversely correlated with the mSASSS, while the other biomarkers increased with increasing score (Fig. 3) . Osteocalcin was therefore combined with C2M, C3M and C6M in a composite index taking into account this relationship. The correlation with mSASSS was slightly increased using the composite index (Fig. 4) .
Discussion
The present study is the first to describe the remodeling process of different MMP-derived collagen species in AS by using a panel of novel collagen connective tissue turnover biomarkers. We found that all the MMP-derived collagen biomarkers were significantly elevated in AS patients compared with age-matched controls, indicating that AS patients have higher connective tissue turnover. In contrast, the non-collagen-related biomarker osteocalcin was not elevated in AS patients [17] . Others have evaluated osteocalcin in AS, showing that bone formation is elevated in these patients [18] . This discrepancy may be caused by a shift in homeostasis of the normal turnover depending on Fig. 3 Correlations between individual and combined biomarkers and mSASSS in the AS patients. a C1M; b C2M; c C3M; d C4M; e C6M; f Osteocalcin. Data were log-transformed, and the correlations were calculated using Pearson's correlation test Recently, a range of novel assays has become available to investigate these processes. In particular, collagen degradation assays, detecting fragments of the collagen specific for the remodeling of various connective tissues (types I, II and III) [19, 20] including bone and articular cartilage (type II) [21] , have been made available. In addition, collagen degradation biomarkers of the basement membrane matrix and muscle tissue (i.e., types IV and VI) have recently been developed by our group [unpublished data]. Together these technologies may provide important insight into the collagen turnover profile of different pathologies and thereby enable the understanding of the intricate relationship between connective tissue turnover and inflammation.
There are considerable limitations in the information provided by standard clinical and laboratory parameters to guide treatment decisions. Consequently, there has been particular interest in evaluating biomarkers in AS that reflect disease activity and predict structural progression [22] [23] [24] [25] . For disease activity, CRP and ESR lack the sensitivity seen in RA, as these markers are elevated in only about 50% of AS patients [26] . CRP was not significantly elevated in the current cohort. Unlike RA, they also correlate poorly with clinical measures of disease activity, although good correlations have been noted with MRI assessment of inflammation in the spine [27, 28] . In contrast to RA, they do not appear to predict the progression of structural damage although as for RA, CRP does predict clinical response to anti-TNF therapy [29, 30] . In that context, we demonstrated that a combination of several of the biomarkers correlated with mSASSS, which might indicate that serological biomarkers can be used for describing disease burden. Emphasizing the need for a composite prediction model, there was only a weak association between mSASSS and the individual biomarkers.
Biochemical markers measured in serum, plasma and urine are often products of local pathological events in which many local specific events contribute to a particular pool of the marker. C1M and C3M are derived by the degradation of type I and type III collagens, respectively. Both collagens are central components of most connective tissues, and the turnover of both collagens is high [31] . Inflammation accelerates the turnover of both of these markers, commonly known as scar healing. This contribution to the systemic levels of these markers in AS could arise from the excessive remodeling of the joint; however, additional contributions are most likely derived from multiple organs of the body affected by inflammation. The contribution of each of the biochemical markers of major tissues still needs to be carefully investigated. C2M describes the degradation of type II collagen, which only resides in the cartilage [32] . Hence, C2M is a measure of cartilage loss, which is an important pathogenesis of AS and other SpAs. Type IV collagen degradation, measured by the neoepitope C4M, is the major collagen of the basal lamina [33] . A high level of C4M is expected in neovascularization and endothelial/epithelial disruption and expansion. Type VI collagen is a major component of microfibrils, and perturbation in the level of type VI collagen has been observed in a wide range of connective tissue disorders such as RA and systemic sclerosis [34] . Type VI collagen is believed to be an important collagen for the maintenance of tissue stability, and elevated levels of the turnover marker C6M could be interpreted as loss of tissue integrity. Although complex, these advanced biochemical markers may assist in understanding the pathophysiology of AS and other diseases involving increased ECM remodeling. In fact, in current study, we observed odd ratios ranging 8-23 that outperform the otherwise available diagnostic markers [e.g., radiography and CRP).
Assessment of biomarkers reflecting bone turnover in SpA has shown variable results depending on the stage and activity of disease. Many studies have reported lower levels of markers of bone resorption in SpA than in RA [35] . A major inhibitor of osteoblastogenesis, DKK-1, was markedly elevated in RA but was not predictive for AS [36] , while sclerostin was increased in RA and reduced in AS [37] . These changes are consistent with the excess bone formation observed in AS and impaired formation in RA. In current study, we did not observe significantly elevated level of bone formation measured by osteocalcin. However, we did find that there was an inverse relationship between osteocalcin and the mSASS score, which could indicate that bone formation in AS is time point specific. One of the earlier events of AS is the development of bone spurs, such as syndesmophytes and enthesiophytes, which contribute to ankylosis of joints and poor physical function [38] . We speculate that by use of a selected diverse biochemical marker set, researcher may be able to use these as diagnostic tools and provide better patient characteristics.
There are a range of limitations of the current study. The limitations are, most importantly, the small sample size and that the clinical assessment was done by mSASSS. mSASSS assesses the cervical and lumbar spine by radiography, and thus it does not assess important AS-associated events such as inflammation and joint health. These and other parameters may be better assessed by advanced MRI technologies. Lastly, the patient history was not available. Different treatment strategies could influence the output of the markers. This has to be investigated more thoroughly in larger and better described population. Thus, the current set of markers would be highly interesting to investigate a population with clinical description done by advanced MRI, enabling separation of disease feature and correlation of the individual markers with those.
Conclusion
In conclusion, the results indicate an independent relationship between the turnover of the connective tissue and cartilage degradation. We developed five new markers of ECM turnover and combined C2M (cartilage degradation), C3M (connective tissue turnover), C6M (microfibril degradation) and osteocalcin (bone formation), which better described the clinical status of the AS patients. In the current context, this use of biochemical markers in AS emphasizes that biochemical marker of bone and cartilage may be applied to SpA in well-controlled settings and studies. We speculate that these markers will be valuable tools for the prediction of treatment efficacy (who will respond to a given intervention); for personal healthcare and personalized medicine; and for the identification of disease progression and those patients most need of treatment.
